Analysis of p53 expression in partial hydatidiform mole and hydropic abortion

Abstract

BACKGROUND: Gestational trophoblastic disease (GTD) is a heterogeneous group of disorders characterized by abnormal trophoblast tissue. Molar and non-molar hydropic placental changes are the most common forms of GTD. Differential diagnosis of GTD is sometimes problematic. Recently, p53 expression was identified as a good marker for distinguishing GTD types.

AIMS:Comparison of p53 expression in partial hydatidiform mole (PHM) and hydropic abortion.

METHODS: In this prospective cross-sectional study, molar and non-molar hydropic pregnancy specimens were collected. Immunohistochemical staining, based on the Labeled Streptavidin Biotin (LSAB) technique, was carried out on multiple 4mm paraffin block sections prepared from formalin-fixed trophoblastic tissues. Polymer-based Envision was used to assess p53 tumor suppressor protein immunoreactivity. p53 expression was then compared between both groups.

RESULTS: In the study, 40 patients were included: 20 with confirmed PHM and 20 with hydropic pregnancy. p53 protein was positive in 60% of patients with PHM and 25% of patients with hydropic pregnancy. The p53 positive rate was significantly higher in patients with PHM (p = 0.027). Moreover, patients with PHM had a significantly high grade of staining (p<0.001).

CONCLUSION: Our findings indicate that immunohistochemical analysis of p53 protein can be used to distinguish PHM and hydropic pregnancy.

Keywords

Partial hydatidiform mole / hydropic abortion / p53 expression

References

[1] Al-Bozom I A (2000). p53 and Bcl-2 oncoprotein expression in placentas with hydropic changes and partial and complete moles. APMIS, 108(11): 756–760

[2] Chen Y X, Shen  D H, Gu  Y Q, Zhong  P P, Xie  J L, Song  Q J, Zhang  Y L, Wen  J (2011). Immunohistochemistry of p57 and p53 protein in differential diagnosis of hydropic abortion, partial and complete hydatidiform mole. Chin J Pathol (Zhonghua Bing Li Xue Za Zhi), 40(10): 694–697

[3] Almasi A, Almassinokiani  F, Akbari P  (2014). Frequency of molar pregnancies in health care centers of tehran, Iran. J Reprod Infertil, 15(3): 157–160

[4] Berchuck A, Kohler  M F, Marks  J R, Wiseman  R, Boyd J ,  Bast R C  Jr (1994). The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol, 170(1 Pt 1): 246– 252

[5] Carey L, Nash  B M, Wright  D C (2015). Molecular genetic studies of complete hydatidiform moles. Transl Pediatr, 4(2): 181–188

[6] Chiu P M, Ngan  Y S, Khoo  U S, Cheung  A N (2001). Apoptotic activity in gestational trophoblastic disease correlates with clinical outcome: assessment by the caspase-related M30 CytoDeath antibody. Histopathology, 38(3): 243–249

[7] Singh Y A, Singh  L S, Singh  L R, Liyak  P, Vaz A (2016) . A study of molar pregnancy at tertiary centre of India. Iosr J Dental Med Sci, 15(9): 49–52

[8] Hasanzadeh M, Sharifi  N, Farazestanian M ,  Nazemian S S ,  Madani Sani F  (2016). Immunohistochemistry study of P53 and C-erbB-2 expression in trophoblastic tissue and their predictive values in diagnosing malignant progression of simple molar pregnancy. Iran J Cancer Prev, 9(3): e4115

[9] Masood S, Kehar  S I, Shawana  S, Aamir I  (2015). Differential expression of p63 in hydropic and molar gestations. J Coll Physicians Surg Pak, 25(3): 198–201

[10] Ngan H Y, Seckl  M J, Berkowitz  R S, Xiang  Y, Golfier F ,  Sekharan P K ,  Lurain J R  (2015). Update on the diagnosis and management of gestational trophoblastic disease. Int J Gynaecol Obstet, 131(Suppl 2): S123–S126

[11] Ozaki T, Nakagawara  A (2011). Role of p53 in cell death and human cancers. Cancers (Basel), 3(1): 994–1013

[12] Rath G, Soni  S, Prasad C P ,  Salhan S ,  Jain A K ,  Saxena S  (2011). Bcl-2 and p53 expressions in Indian women with complete hydatidiform mole. Singapore Med J, 52(7): 502–507

[13] Schammel D P, Bocklage  T (1996). p53 PCNA, and Ki-67 in hydropic molar and nonmolar placentas: an immunohistochemical study. Int J Gynecol Pathol, 15(2): 158–166

[14] Soragni A, Janzen  D M, Johnson  L M, Lindgren  A G, Thai-Quynh Nguyen  A, Tiourin E ,  Soriaga A B ,  Lu J, Jiang  L, Faull K F ,  Pellegrini M ,  Memarzadeh S ,  Eisenberg D S  (2016). A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell, 29(1): 90–103

[15] Standard Immunohistochemistry Staining Method, Labeled Streptavidin Biotin (LSAB) Method [online]. Available from: 160;Accessed Feb 11, 2007

[16] Wei D, Wu  Q, Shi H  (2014). Apoptosis and p53 expression in the placental villi of females with unexplained recurrent spontaneous abortion. Exp Ther Med, 7(1): 191–194

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag Berlin Heidelberg